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The author regrets that an error was published within the Results section of the Abstract. The correct text is printed below.
Results: For morning peak expiratory flow (mPEF), all four budesonide treatments resulted in statistically significant
improvements from baseline and, after 12 weeks, the changes in all four groups were statistically significantly greater than
placebo. In patients receiving early treatment, no significant differences were seen between budesonide doses. In patients
with established symptoms, 800 mg/day improved mPEF significantly more than 200 mg/day. The 200 mg/day dose in the
early treatment group improved mPEF significantly more than in the delayed treatment group. Changes in forced expiratory
volume in 1 s (FEV1), the concentration of inhaled histamine causing a 20% drop in FEV1, and use of as-needed medication
behaved in very similar ways to mPEF. Asthma symptoms were reduced in all budesonide groups without a difference
between doses.DOI of original article: 10.1016/j.rmed.2007.12.029.
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